Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity

Area of Science:

• Biochemistry
• Toxicology
• Pharmacology

Background:

• Ifosfamide (IFO) is a chemotherapy drug with known nephrotoxicity.
• Thioredoxin reductase (TrxR) is a key antioxidant enzyme in cellular defense.
• Understanding the mechanisms of IFO-induced kidney damage is crucial for patient safety.

Purpose of the Study:

• To investigate the role of renal thioredoxin reductase (TrxR) activity in ifosfamide (IFO)-induced acute renal failure (ARF).
• To determine the impact of IFO on other antioxidant systems, such as glutathione.

Main Methods:

• Mice were treated with varying doses of IFO.
• Renal TrxR activity and glutathione levels were measured.
• Auranofin (TrxR inhibitor) and buthionine sulfoximine (glutathione synthesis inhibitor) were used to probe mechanisms.
• Acute renal failure (ARF) was assessed dose-dependently.

Main Results:

• IFO significantly decreased renal TrxR activity and induced ARF in a dose-dependent manner.
• Inhibition of TrxR by auranofin mimicked IFO's nephrotoxic effects.
• IFO at higher doses depleted glutathione, exacerbating nephrotoxicity and leading to lethality.
• Combined inhibition of TrxR and glutathione synthesis resulted in more severe ARF than inhibiting either system alone.

Conclusions:

• Inhibition of renal TrxR activity is a pivotal mechanism underlying IFO-induced ARF.
• Lower baseline renal glutathione levels may predispose individuals to IFO-induced nephrotoxicity.
• Targeting both thioredoxin and glutathione systems leads to more severe toxicological outcomes.